Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:TEM News 8 October 2025 - 6 December 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI shares closed near $76.70 on December 5, 2025, up 52% from a year earlier, with a market cap around $13.6 billion. The stock trades at a forward price-to-sales ratio of 8–10x and a negative P/E near –65. Recent analyst notes and institutional buying have fueled debate over valuation as volatility remains high. Tempus went public in June 2024 and focuses on AI-driven precision medicine.
6 December 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum accelerated in 2025 as the company delivered strong results and AI breakthroughs. By early September 2025, TEM had more than doubled its IPO price, reaching the high-$80s to $90 range ts2.tech. A series of catalysts (detailed below) then propelled the
9 October 2025
·
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Company Overview and Mission Tempus AI, Inc. is an American health technology company founded in 2015 by entrepreneur Eric Lefkofsky (best known as co-founder of Groupon). Headquartered in Chicago, Tempus was born from Lefkofsky’s personal mission to improve cancer care after his wife’s battle with breast canceren.wikipedia.org. The company’s core focus is on applying AI and data analytics to personalized medicine. Tempus has built what it calls an “operating system” for healthcare: a platform that ingests vast amounts of clinical and molecular data (gene sequences, lab tests, medical records, imaging, etc.) and makes it accessible for treatment decisions and researchinsidermonkey.com. Its goal is to enable doctors and
8 October 2025
···

Stock Market Today

Amazon stock slides on $200 billion AI spending plan — what investors watch before Monday

Amazon stock slides on $200 billion AI spending plan — what investors watch before Monday

8 February 2026
New York, Feb 8, 2026, 05:42 EST — Market closed Amazon.com Inc shares (AMZN.O) last closed at $210.32 on Friday, down 5.6%, as traders headed into the weekend still focused on the bill for the company’s AI build-out. The move matters because investors have begun to treat Big Tech’s artificial-intelligence spending as a near-term drag, not a free option. “The AI build-out trade … got too pricey,” said Andrew Wells, chief investment officer at SanJac Alpha. (Reuters) That shift is cracking the old “everything AI wins” trade. “The market is no longer tolerating spending for spending’s sake,” said Mark Hawtin,
Bradesco stock price slides after earnings — what BBDC4 traders watch before Monday’s open

Bradesco stock price slides after earnings — what BBDC4 traders watch before Monday’s open

8 February 2026
Bradesco preferred shares fell 2.6% to R$20.61 Friday after the bank reported fourth-quarter net income of 6.5 billion reais and set 2026 targets for loan growth and margins. The bank guided loan book expansion of 8.5% to 10.5% and projected higher operating expenses. Investors await Brazil’s inflation data Tuesday for rate signals. Bradesco’s preferred ADR closed at $3.98 in New York.
Go toTop